| Name | Title | Contact Details |
|---|---|---|
Dimitris Agrafiotis |
Chief Digital Officer | Profile |
Developing the next generation of immuno-oncology therapeutics
MapLight Therapeutics is developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders. Today, there are few therapeutic options for people living with conditions such as schizophrenia, Alzheimer`s disease, Parkinson`s, and autism spectrum disorder. Available treatments are limited by modest efficacy and significant side effects. MapLight is committed to redefining this standard of care. The company`s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and treat those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of the two groundbreaking technologies, optogenetics and STARmap.
Personalized medicine, drug discovery, diagnostic testing, and foundational genomic research all start with bioinformatics. The world`s largest research institutions use Seven Bridges` software platform to help them analyze, store, and act on genomic and other biological data.
Plexxikon is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BIA Separations is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.